Table 2

Changes in lipoprotein subclass measurements and physiological variables by case/control status

Controls (n = 73)

Participants (n = 73)

Variable

Baseline

Week 12

Week 52

% change

Baseline

Week 12

Week 52

% change

Between group

p valuea


Lipoprotein subclassb

VLDL and chylomicron particles (nmol/L)

Tot VLDL/chylo

82.0 ± 45.3

80.2 ± 42.6

81.9 ± 47.2

-0.2

87.5 ± 39.6

96.2 ± 43.3

88.5 ± 45.3

+1.2

0.84

Lg VLDL/chylo

4.6 ± 6.3

5.2 ± 6.2

4.5 ± 5.4

-1.2

8.2 ± 6.8

4.7 ± 5.3c

5.8 ± 7.0d

-29.4

0.03

Medium VLDL

38.1 ± 28.5

37.4 ± 24.3

37.8 ± 29.5

-0.9

39.7 ± 25.7

49.8 ± 31.8c

42.0 ± 28.6

+6.0

0.50

Small VLDL

39.3 ± 19.9

37.6 ± 22.1

39.6 ± 19.9

+0.6

39.7 ± 17.2

41.7 ± 18.7

40.7 ± 21.7

+2.6

0.80

LDL particles (nmol/L)

Total LDL

1253 ± 367

1242 ± 422

1249 ± 414

-0.4

1437 ± 477

1291 ± 445c

1317 ± 452d

-8.3

0.04

Large LDL

337 ± 211

315 ± 191

317 ± 208

-5.8

251 ± 218

215 ± 152

263 ± 174

+4.5

0.24

Intermed LDL

45.8 ± 38.5

55.6 ± 56.2

43.1 ± 44.6

-5.8

72.6 ± 50.1

50.6 ± 43.4c

47.3 ± 46.3c

-34.9

< 0.01

Small LDL

870 ± 434

872 ± 445

888 ± 457

+2.1

1113 ± 478

1025 ± 432

1007 ± 470d

-9.5

0.04

HDL particles (μmol/L)

Total HDL

34.7 ± 6.7

35.2 ± 6.1

35.2 ± 6.4

+1.7

32.1 ± 5.6

29.0 ± 5.0c

32.3 ± 5.9

+0.6

0.64

Large HDL

6.4 ± 3.5

6.7 ± 3.3

6.5 ± 3.5

+1.4

4.6 ± 3.4

4.3 ± 2.2

5.2 ± 2.9

+12.7

0.19

Medium HDL

4.9 ± 4.6

5.2 ± 5.1

4.5 ± 4.5

-8.6

5.6 ± 4.7

4.2 ± 4.1c

5.2 ± 5.3

-7.8

0.70

Small HDL

23.1 ± 7.0

23.0 ± 7.0

24.2 ± 6.7

+4.6

21.7 ± 5.8

20.6 ± 4.7

22.1 ± 6.9

+2.2

0.49

Mean particle sizes (nm)

VLDL size

50.6 ± 9.0

51.8 ± 8.2

50.9 ± 7.5

+0.6

55.6 ± 10.4

48.2 ± 8.6c

50.2 ± 9.5c

-9.7

< 0.01

LDL size

20.7 ± 0.9

20.7 ± 0.8

20.7 ± 0.8

-0.2

20.2 ± 0.8

20.2 ± 0.6

20.4 ± 0.7

+0.8

0.03

HDL size

8.8 ± 0.4

8.9 ± 0.4

8.8 ± 0.4

-0.4

8.6 ± 0.3

8.7 ± 0.3

8.7 ± 0.4d

+1.0

< 0.01

Physiological variablese

BMI

28.2 ± 3.7

28.0 ± 3.9

28.3 ± 3.8

+0.4

34.0 ± 7.0

31.4 ± 6.3c

30.7 ± 6.6c

-9.9

< 0.01

Systolic BP

133 ± 17

128 ± 15d

126 ± 13d

-5.4

136 ± 17

122 ± 14c

127 ± 16c

-6.6

0.55

Diastolic BP

78.9 ± 9.2

78.1 ± 8.0

77.3 ± 8.4

-2.0

80.8 ± 9.8

72.6 ± 8.3c

76.0 ± 9.4d

-6.0

0.08

HDL

50.5 ± 13.7

51.9 ± 12.7

48.1 ± 13.5d

-4.9

43.7 ± 13.1

37.5 ± 9.0c

42.8 ± 10.3

-2.1

0.26

LDL

111 ± 33

110 ± 35

112 ± 36

+1.0

111 ± 39

96 ± 34c

107 ± 34

-3.9

0.23

Tot cholesterol

191 ± 42

192 ± 45

191 ± 46

+0.2

193 ± 47

167 ± 44c

183 ± 43d

-5.5

0.03

Triglycerides

148 ± 100

158 ± 140

152 ± 89

+2.8

189 ± 99

167 ± 73

168 ± 97

-11.3

0.05

Bruce

10.4 ± 2.8

10.6 ± 2.7

10.3 ± 2.8

-1.4

6.6 ± 2.2

8.5 ± 2.3c

9.0 ± 2.7c

+37.2

< 0.01

Fram risk

7.2 ± 6.7

6.8 ± 6.5

7.2 ± 7.2

+0.6

11.0 ± 8.6

10.2 ± 8.5d

10.1 ± 7.8d

-7.9

< 0.01


Values are presented as mean ± SD; differences between table values and calculated values are due to rounding; % change = week 0–52. a: p values resulting from independent samples t-tests (two-tailed) of Baseline to Week 52 changes in Ornish participants compared to the control group, b: there was no missing data, c: values at Week 12 and Week 52 were significantly different from Baseline at p < 0.001 based on repeated-measures ANOVA with time point as the within-subjects factor and cohort type as the between-subjects factor, d: values at Week 12 and Week 52 were significantly different from Baseline at p < 0.05 based on repeated-measures ANOVA with time point as the within-subjects factor and cohort type as the between-subjects factor, e: there was < 4.2% missing data.

Decewicz et al. Lipids in Health and Disease 2009 8:26   doi:10.1186/1476-511X-8-26

Open Data